Araxes Pharma LLC

Intel Corporation

Kura Oncology, Inc.

Future Wei Technologies, Inc.

University of Michigan

Telefonaktiebolaget Lm Ericsson (publ)

Apple Inc.

Ford Global Technolgoies, LLC

Novartis Ag

Life Technologies Corporation

Irm LLC

Tao Wu

Pingda Ren

Liansheng Li

Yi Liu

Jun Feng

Yuan Liu

Yun Long

Yi Wang

Jolanta Grembecka

Tomasz Cierpicki

Dmitry Borkin

Jonathan Pollock

Zhichao Zhang

Mihir K Roy

Patrick Hosein

Szymon Klossowski

Kemal Aygun

Islam A Salama

Mohammad Mamunur Rashid

Yang Tang

Young Hoon Kwon

Anthony C K Soong

Young Cheul Yoon

Shiau-He Tsai

Mark S Hlad

Gang Xiong

Rath Vannithamby

Kyu Oh Lee

Arnab Kumar Chatterjee

Wei-Lun Kane Jen

David C Tully

Advait Suresh Nagle

Yueli Liu

Kelli L Kuhen

Yi Li

Manohar S Konchady

Tolga Memioglu

Debdeep Chatterjee

Satish Chandra Jha

Zhiguo Qian

Thawatt Gopal

Robert Wendell Heath, Jr

Duxin Sun

Gaurav Chawla

Robert W Heath

Jonas Lennart Wiorek

Hongzhi Miao

Yajun Kou

Wanshi Chen

Oghenekome Oteri

Srinivasan Balasubramanian

Philippe J Sartori

Yunsong Yang

Ralph Akram Gholmieh

David Comstock

Jianmin Lu

Quanzhong Gao

Qinglei Zhang

Long Duan

Nicholas Randolph Watts

Xavier De Mollerat Du Jeu

Christian B Schlegel

Parul Angrish

Zhiwei Yang

Patrick Ahamad Hosein

Charavana K Gurumurthy

Yun Ho Lee

Reynaldo Alberto Olmedo

Anthony Soong

Jeffrey Lee

Kristin Wiederholt

Charavanakumara Gurumurthy

Seong-Jun Oh

Jerry John

Nicolas R Watts

Hsein Woo

Francis Burrows

Linda V Kessler

Jingchuan Zhang, I

Alana K Borum

Depdeep Chatterjee

Shiau-He Shawn Tsai

Yun Oliver Long

Patrick A Hosein

Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.

Covalent inhibitors of KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have one of the following structures (I), (II) or (III): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R, R, R, R, R, R, R, R, R, R, A, B, G, G, L, L, m, m, n, x, y, X and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Substituted quinazoline compounds and methods of use thereof

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, have the following structure: wherein A, L, L, Q, R, R, R, R, R, R, R, R, Y, and Z are as exemplified herein. Pharmaceutical compositions comprising such compounds, methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, and methods associated with preparation of such compounds are also provided.

Substituted piperazines as inhibitors of KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R, L, L, L, A, A, A, A, G, G, E, W, X, Y, Z, m, and n are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer

The present disclosure provides methods for treating hematological malignancies and Ewings sarcoma using menin inhibitors. Compositions for use in these methods are also provided.

Methods for treating hematological malignancies and Ewing's sarcoma

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R, R, R, R, R, R, G, G, L, L, m, m, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Substituted quinazolines as inhibitors of KRAS G12C

The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.

Thienopyrimidine and thienopyridine compounds and methods of use thereof

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins with compositions of Formula (II-A). The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions of Formula (II-A) for use in these methods are also provided. 

Substituted inhibitors of menin-MLL and methods of use

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R, R, R, R, R, R, R, R, R, L, L, E, mand mare as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided. 

Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS

The present disclosure provides compounds of Formula (I-A) for inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compounds are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. 

Bridged bicyclic inhibitors of menin-MLL and methods of use

The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.

Methods and compositions for inhibiting the interaction of menin with MLL proteins

Described is an Evolved Node-B (eNB) comprising one or more processors to generate a first transmission for a first Cellular Internet-of-Things (CIoT) device and a second transmission for a second CIoT device. The first transmission may be generated for a first Narrowband (NB) channel, and the second transmission may be generated for a second NB channel. The first and second transmissions may include the same set of system information. Also described is a CIoT device comprising one or more processors to process a System Information (SI) transmission on one of a plurality of NB channels, and to process and extract information from a PSS and/or SSS transmission on a set of subcarriers corresponding to a set of frequency bands. The plurality of NB channels are within a wireless communication system bandwidth, and at least two of the plurality of NB channels correspond to portions of the wireless communication system bandwidth outside the set of frequency bands.

System and methods for system operation for narrowband-LTE for cellular IoT

A land grid array (LGA) land pad having reduced capacitance is disclosed. The conductive portion of a land pad that overlaps a parallel ground plane within the substrate is reduced by one or more non-conductive voids though the thickness of the conductive portion of the land pad. The voids may allow the contact area of the land pad, as defined by the perimeter of the land pad, to remain the same while reducing the conductive portion that overlaps the parallel ground plane. Capacitance between the land pad and the parallel ground plane is reduced by an amount proportional to the reduction in overlapping conductive area.

Reduced capacitance land pad

A coreless package substrate with dual side solder resist layers is disclosed. The coreless package substrate has a top side and a bottom side opposite of the top side and includes a single build-up structure formed of at least one insulating layer, at least one via, and at least one conductive layer. The coreless package substrate also includes a bottom plurality of contact pads on the bottom side, and a top plurality of contact pads on the top side. A bottom solder resist layer is on the bottom side, and a top solder resist layer is on the top side. The concept of dual side solder resist is extended to packages with interconnect bridge with C4 interconnection pitch over a wide range.

Methods of forming a package substrate

Growing community of inventors

Carlsbad, CA, United States of America

Tao Wu